Cargando…
Expansion of opiate agonist treatment: an historical perspective
Untreated opiate addiction remains a major health care crisis in New York and in most other urban centers in America. Optimism for closing the gap between need and demand for treatment and its availability has greeted the recent approval of a new opiate medication for addiction, buprenorphine – whic...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1557846/ https://www.ncbi.nlm.nih.gov/pubmed/16859549 http://dx.doi.org/10.1186/1477-7517-3-20 |
_version_ | 1782129420801146880 |
---|---|
author | Newman, Robert G |
author_facet | Newman, Robert G |
author_sort | Newman, Robert G |
collection | PubMed |
description | Untreated opiate addiction remains a major health care crisis in New York and in most other urban centers in America. Optimism for closing the gap between need and demand for treatment and its availability has greeted the recent approval of a new opiate medication for addiction, buprenorphine – which unlike methadone may be prescribed by independent, office-based practitioners. The likelihood of buprenorphine fulfilling its potential is assessed in the light of the massive expansion of methadone treatment more than 30 years earlier. It is concluded that the key, indispensable ingredient of success will be true commitment on the part of Government to provide care to all those who need it. |
format | Text |
id | pubmed-1557846 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-15578462006-09-01 Expansion of opiate agonist treatment: an historical perspective Newman, Robert G Harm Reduct J Commentary Untreated opiate addiction remains a major health care crisis in New York and in most other urban centers in America. Optimism for closing the gap between need and demand for treatment and its availability has greeted the recent approval of a new opiate medication for addiction, buprenorphine – which unlike methadone may be prescribed by independent, office-based practitioners. The likelihood of buprenorphine fulfilling its potential is assessed in the light of the massive expansion of methadone treatment more than 30 years earlier. It is concluded that the key, indispensable ingredient of success will be true commitment on the part of Government to provide care to all those who need it. BioMed Central 2006-07-21 /pmc/articles/PMC1557846/ /pubmed/16859549 http://dx.doi.org/10.1186/1477-7517-3-20 Text en Copyright © 2006 Newman; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Newman, Robert G Expansion of opiate agonist treatment: an historical perspective |
title | Expansion of opiate agonist treatment: an historical perspective |
title_full | Expansion of opiate agonist treatment: an historical perspective |
title_fullStr | Expansion of opiate agonist treatment: an historical perspective |
title_full_unstemmed | Expansion of opiate agonist treatment: an historical perspective |
title_short | Expansion of opiate agonist treatment: an historical perspective |
title_sort | expansion of opiate agonist treatment: an historical perspective |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1557846/ https://www.ncbi.nlm.nih.gov/pubmed/16859549 http://dx.doi.org/10.1186/1477-7517-3-20 |
work_keys_str_mv | AT newmanrobertg expansionofopiateagonisttreatmentanhistoricalperspective |